>I always thought Vertex looked like the best long term bet in the Hepatitis area, though they're still early stage and the stock is now very expensive (lots of competition in that space too). Idenix should get to market a lot sooner, and has a strong partnership, though their drug doesn't appear to have near the potential of Vertex's VX-950.<
Just to be clear: you’re talking about the market for HCV, which I consider icing on IDIX’s valuation cake. If IDIX and NVS merely capture a large share of the market in HBV, IDIX shareholders ought to do quite well from the current price level.
Market Data 
Markets 
AI
